An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials.

doi:10.1158/1078-0432.CCR-24-0459

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials.

Clinical cancer research : an official journal of the American Association for Cancer Research - 3 Sept 2024

Jank Paul, Karn Thomas, van Mackelenbergh Marion, Lindner Judith, Treue Denise, Huober Jens, Engels Knut, Solbach Christine, Diebold Kurt, Marmé Frederik, Müller Volkmar, Schneeweiss Andreas, Sinn Hans-Peter, Fehm Tanja, Schem Christian, Stickeler Elmar, Fasching Peter, Budczies Jan, Felder Bärbel, Nekljudova Valentina, Holtschmidt Johannes, Untch Michael, Denkert Carsten, Loibl Sibylle

Abstract excerpt

PURPOSE: The PI3K signaling pathway is frequently dysregulated in breast cancer, and mutations in PIK3CA are relevant for therapy resistance in HER2-positive (HER2pos) breast cancer. Mutations in exons 9 or 20 may have different impacts on response to neoadjuvant chemotherapy-based treatment regimens. EXPERIMENTAL DESIGN: We investigated PIK3CA mutations in 1,691 patients with early breast cancer who were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Breast Neoplasms

Share to Class I Phosphatidylinositol 3-Kinases

Share to Exons

Share to Neoadjuvant Therapy

Share to Receptor, ErbB-2

Share to Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 38837894
DOI: 10.1158/1078-0432.CCR-24-0459

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials.PMID 38837894Read ↗

PIK3CA mutations and their response to neoadjuvant treatment in early breast cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.Semantic proximity Read ↗

PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.Semantic proximity Read ↗

PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.Semantic proximity Read ↗

Analysis of PIK3CA Mutations with Clinicopathological Features and Prognosis in Breast cancer patients with Undergoing Neoadjuvant TherapySemantic proximity Read ↗

Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.Semantic proximity Read ↗

Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer.Semantic proximity Read ↗

Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.Semantic proximity Read ↗

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.Semantic proximity Read ↗

PIK3CA mutations in breast cancerSemantic proximity Read ↗

High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.Semantic proximity Read ↗

PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.